BSX Today - Aug 08: Mixed Signals on Sales

Impossibile aggiungere al carrello

Puoi avere soltanto 50 titoli nel carrello per il checkout.

Riprova più tardi

Rimozione dalla Lista desideri non riuscita.

Riprova più tardi

Non è stato possibile aggiungere il titolo alla Libreria

Per favore riprova

Non è stato possibile seguire il Podcast

Per favore riprova

Esecuzione del comando Non seguire più non riuscita

BSX Today - Aug 08: Mixed Signals on Sales

Ascolta gratuitamente

Vedi i dettagli del titolo

Offerte di stagione | 0,99 €/mese per i primi 3 mesi

A seguire 9,99 €/mese – si applicano condizioni. Puoi disdire mensilmente.

A proposito di questo titolo

Hey there! It’s Joey, your friendly investor buddy, here to break down what went down with Boston Scientific today. So, BSX had a pretty chill day, barely moved, closing up just a smidge at 49.31. Yeah, it was one of those days where not much happened, but let’s unpack it.

So, what’s the scoop? Well, the stock got a little bump from some insider action. One of the directors, David Habiger, bought up 2,100 shares. You know how that goes—when insiders buy, it usually perks up some ears. But honestly, it didn't spark a big rally, and the overall vibe was kinda flat.

Now, here’s where it gets interesting. There’s some chatter about BSX’s WATCHMAN sales, which are under the microscope after Needham cut the stock's price target. Sounds like they’re not super confident about those numbers, and that’s a bummer. Plus, in a recent earnings call, the CEO mentioned a few surprises that led to a cut in the FY26 guidance. So, yeah, mixed signals all around.

One thing to keep an eye on? The market's gonna be watching how those sales trends play out in the coming quarters. If they can turn things around, that could change the game.

Alright, that’s the lowdown for today! Just remember, this info is for fun and to keep you in the loop, not financial advice. Catch you later!

Ancora nessuna recensione